Clinical trial · Interventional
Neoadjuvant Chemotherapy Response Assessment by Combined PET-MRI in Borderline and Locally Advanced Pancreatic Adenocarcinoma.
Neoadjuvant Chemotherapy Response Assessment by Combined PET-MRI in Borderline and Locally Advanced Pancreatic Adenocarcinoma. PACMI (Pancreatic AdenoCarcinoma Multimodality Imaging)
NCT03202199CI-TRIAL-00028777PACMIunknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study was to assess the diagnostic accuracy of PET-MRI to predict resectability of pancreatic adenocarcinoma after neoadjuvant chemotherapy ± radiation therapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Adenocarcinoma | Pancreatic Adenocarcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| PET/MRI | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- PET/MRI
- description
- PET/MRI examination
- interventionNames
- Device: PET/MRI
Primary outcomes (1)
- measure
- Accuracy of PET/MRI to predict pancreatic adenocarcinoma rescetability after neaadjuvant treatment
- timeFrame
- PET/MRI performed less than one month before the surgery
Secondary outcomes (3)
- measure
- Accuracy of tumor size, ADC, D, D*, F and SUVmax at baseline, before surgery and their variations for resectability
- timeFrame
- PET MRI performed at baseline (15 days before the treatment beginning) less than one month before the surgery
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age \> 18yo * Locally advanced or borderline resectable pancreatic adenocarcinoma, according to the NCCN classification * Eligible for neoadjuvant chemotherapy ± radiation therapy, according to the local tumor board * With contraception if fertile woman * With informed consent obtained * Affiliated to French health care system Exclusion Criteria: * Previous treatment for the pancreatic adenocarcinoma * Metastases * Contra-indication to MRI acquisition (pace maker, metallic device, ..) * Contra-indication to PET acquisition (non controlled diabetes with glycaemia \> 11 mmol/L) * Pregnancy or breast feeding * Patient unable to give his consent
References
Publications (0)
Data not yet available
No reference posted for this study.